This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Jack Kramarczyk
Director, Technical Development at Moderna Therapeutics


Jack Kramarczyk is Director of late stage development for Moderna’s Technical Development department responsible for scaling out the process and analytical teams in support of late stage product candidates. He has been the technical lead for Moderna’s six-valent CMV vaccine and for Moderna’s family of multi-valent seasonal Flu vaccines. Jack was a lab head for four years within the Lipid Nanoparticle process development team focused on process development and scaleup. Prior to joining Moderna, Jack worked for 15 years at Wyeth BioPharma, Virdante Pharmaceuticals, and Axcella Health developing and scaling-up protein purification processes.

Agenda Sessions

  • Multivalent mRNA Product Strategies